Cancer is a genetic disease caused by genetic instability. Our program in cancer genetics includes a component that emphasizes high throughput refined karyotypic analysis and comprehensive cloning and characterization of all chromosomal aberrations found to be present in specific cancers or cancer cell lines. We have dubbed an aspect of this approach, comprehensive breakpoint cloning and are engaged in a """"""""proof-of-principle"""""""" of a high throughput cost-saving strategy for this work. Another major component involves the development of a patient pathway that emphasizes individualized risk screening, education, counseling, germline testing (for those who choose to be tested), followed by entry into protocols for prevention, surveillance, and targeted therapy. The two prototype cancers for which this program has been initiated are colorectal and breast cancer. The translational research component that supports this program includes molecular diagnostics, biomarkers of risk, genotype/phenotype correlations, and a new approach to anticancer drug screening. In addition, we are invested in initiatives by which we have linked the human physical genomic map with the cytogenetic map, and provided a database and clone repository that can be utilized by the biomedical community at large for cancer genome characterization. The clinical component of this project was tranferred to Dr. Sheila Prindiville in 2005 with the resignation of the Dr. Ilan Kirsch.

Agency
National Institute of Health (NIH)
Institute
Division of Clinical Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01SC007265-11
Application #
7292043
Study Section
(GB)
Project Start
Project End
Budget Start
Budget End
Support Year
11
Fiscal Year
2005
Total Cost
Indirect Cost
Name
Clinical Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Calzone, Kathleen A; Prindiville, Sheila A; Jourkiv, Oxana et al. (2005) Randomized comparison of group versus individual genetic education and counseling for familial breast and/or ovarian cancer. J Clin Oncol 23:3455-64
Roschke, Anna V; Lababidi, Samir; Tonon, Giovanni et al. (2005) Karyotypic ""state"" as a potential determinant for anticancer drug discovery. Proc Natl Acad Sci U S A 102:2964-9
Hadley, Donald W; Jenkins, Jean F; Dimond, Eileen et al. (2004) Colon cancer screening practices after genetic counseling and testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol 22:39-44
Junicke, Henrik; Hart, Jonathan R; Kisko, Jennifer et al. (2003) A rhodium(III) complex for high-affinity DNA base-pair mismatch recognition. Proc Natl Acad Sci U S A 100:3737-42
Roschke, Anna V; Tonon, Giovanni; Gehlhaus, Kristen S et al. (2003) Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 63:8634-47
Hadley, Donald W; Jenkins, Jean; Dimond, Eileen et al. (2003) Genetic counseling and testing in families with hereditary nonpolyposis colorectal cancer. Arch Intern Med 163:573-82
Hausner, P; Venzon, D J; Grogan, L et al. (1999) The ""comparative growth assay"": examining the interplay of anti-cancer agents with cells carrying single gene alterations. Neoplasia 1:356-67